Although inhibition of BRAF oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma, colon cancer patients associated with the same BRAF mutation have poor prognosis showing only a very limited response to this drug. Here, BRAF is linked to colonic neoplasm.